The wide-ranging pact involves as many as 13 drugs and marks the latest example of the growing relationship between Chinese pharmaceutical firms and their U.S. and Europe-based counterparts.
An article from
China competition
The wide-ranging pact involves as many as 13 drugs and marks the latest example of the growing relationship between Chinese pharmaceutical firms and their U.S. and Europe-based counterparts.
Published May 12, 2026
A Bristol Myers Squibb sign hangs on the side of an office building in San Diego, California.
Bristol Myers Squibb turns to China to develop new drugs in newest cross-continent collaboration
Bristol Myers joins Hengrui party in 13-asset deal worth up to $15.2B
Fierce Pharma Asia—BMS-Hengrui's $15B deal; Takeda’s 4.5K layoffs; Daiichi’s oncology ambition
Global drugmakers eye more China biotech deals after record year
Lilly, Gilead lead pharma’s M&A boom
